The effectiveness of agomelatine on headache severity and frequency in episodic migraine without aura; a parallel randomized controlled trial study.
Agomelatine
Headache frequency
Headache severity
Migraine
Journal
BMC neurology
ISSN: 1471-2377
Titre abrégé: BMC Neurol
Pays: England
ID NLM: 100968555
Informations de publication
Date de publication:
02 Jan 2024
02 Jan 2024
Historique:
received:
18
06
2023
accepted:
18
12
2023
medline:
4
1
2024
pubmed:
4
1
2024
entrez:
3
1
2024
Statut:
epublish
Résumé
Migraine is a headache disorder that affects public health and reduces the patient's quality of life. Preventive medication is necessary to prevent acute attacks and medication overuse headaches (MOH). Agomelatine is a melatonin antagonist. This study aimed to determine the effectiveness of agomelatine on the severity and frequency of migraine attacks. The study is a parallel randomized controlled trial with two groups of intervention and control. 400 patients were evaluated. Eligible individuals, including those with episodic migraine headaches without aura between the ages of 18 and 60 years who did not receive preventive treatment beforehand, were enrolled. Also, patients did not receive any specific medications for other diseases. Among these, 100 people met the inclusion criteria and entered the study. These subjects were randomly assigned to one of the two groups. The intervention group received 25 mg of agomelatine daily and the control group received B1. In this study, the effect of agomelatine on the frequency and severity of attacks, mean monthly migraine days (MMD), and migraine disability assessment (MIDAS), were assessed. The study was triple-blind and after three months, a post-test was performed. Data were analyzed using SPSS software. A total of 100 patients were randomly assigned to either intervention or control groups. The prescriber physician and the data collector did not know about the allocation of patients to groups. Before the intervention, there was no significant difference in the headache frequency per month (t=-0.182, df = 98, p = 0.85), mean MMD (p = 0.17), headache severity (p = 0.076), and MIDAS (p = 0.091). After the study, there was a significant difference between the two groups in terms of the headache frequency per month (p = 0.009), and mean of MMD (p = 0.025). There was also a significant difference between pretest and posttest in two groups in the headache severity (p < 0.001) and MIDAS (p < 0.001). Agomelatine can be used as a preventive medication for migraine without aura. It is suggested that agomelatine be studied in comparison with other preventive drugs for patients with migraine. Trial Retrospectively registration= IRCT20230303057599N1. Date: 2023-5-24 The present study is a residency thesis approved by the Tehran University of Medical Sciences.
Sections du résumé
BACKGROUND
BACKGROUND
Migraine is a headache disorder that affects public health and reduces the patient's quality of life. Preventive medication is necessary to prevent acute attacks and medication overuse headaches (MOH). Agomelatine is a melatonin antagonist.
AIMS
OBJECTIVE
This study aimed to determine the effectiveness of agomelatine on the severity and frequency of migraine attacks.
METHODS
METHODS
The study is a parallel randomized controlled trial with two groups of intervention and control. 400 patients were evaluated. Eligible individuals, including those with episodic migraine headaches without aura between the ages of 18 and 60 years who did not receive preventive treatment beforehand, were enrolled. Also, patients did not receive any specific medications for other diseases. Among these, 100 people met the inclusion criteria and entered the study. These subjects were randomly assigned to one of the two groups. The intervention group received 25 mg of agomelatine daily and the control group received B1. In this study, the effect of agomelatine on the frequency and severity of attacks, mean monthly migraine days (MMD), and migraine disability assessment (MIDAS), were assessed. The study was triple-blind and after three months, a post-test was performed. Data were analyzed using SPSS software.
RESULTS
RESULTS
A total of 100 patients were randomly assigned to either intervention or control groups. The prescriber physician and the data collector did not know about the allocation of patients to groups. Before the intervention, there was no significant difference in the headache frequency per month (t=-0.182, df = 98, p = 0.85), mean MMD (p = 0.17), headache severity (p = 0.076), and MIDAS (p = 0.091). After the study, there was a significant difference between the two groups in terms of the headache frequency per month (p = 0.009), and mean of MMD (p = 0.025). There was also a significant difference between pretest and posttest in two groups in the headache severity (p < 0.001) and MIDAS (p < 0.001).
CONCLUSION
CONCLUSIONS
Agomelatine can be used as a preventive medication for migraine without aura. It is suggested that agomelatine be studied in comparison with other preventive drugs for patients with migraine.
TRIAL RETROSPECTIVELY REGISTRATION
UNASSIGNED
Trial Retrospectively registration= IRCT20230303057599N1. Date: 2023-5-24 The present study is a residency thesis approved by the Tehran University of Medical Sciences.
Identifiants
pubmed: 38166859
doi: 10.1186/s12883-023-03516-9
pii: 10.1186/s12883-023-03516-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2Informations de copyright
© 2023. The Author(s).
Références
Steiner TJ, Stovner LJ. Global epidemiology of migraine and its implications for public health and health policy. Nat Reviews Neurol. 2023;19(2):109–17.
doi: 10.1038/s41582-022-00763-1
Alatawi AM, Moria HA, Alharfy AAN, Alotaibi JTA, Ali M, Alyami M, Alzahrani AMMM, Albalawi ZSD, Albalawi MB. The prevalence of migraine headache among the general population and its impact on quality of life in Tabuk City, Saudi Arabia. Med Sci. 2023;27:e48ms2692.
doi: 10.54905/disssi/v27i131/e48ms2692
Ducros A, de Gaalon S, Roos C, Donnet A, Giraud P, Guégan-Massardier E, Lantéri-Minet M, Lucas C, Mawet J, Moisset X. Revised guidelines of the French headache society for the diagnosis and management of migraine in adults. Part 2: pharmacological treatment. Rev Neurol. 2021;177(7):734–52.
doi: 10.1016/j.neurol.2021.07.006
pubmed: 34340810
Ashina M, Katsarava Z, Do TP, Buse DC, Pozo-Rosich P, Özge A, Krymchantowski AV, Lebedeva ER, Ravishankar K, Yu S. Migraine: epidemiology and systems of care. The Lancet. 2021;397(10283):1485–95.
doi: 10.1016/S0140-6736(20)32160-7
Taheri R, Nekuvaght Tak A, Masoudian N. Prevalence of migraine headache in patients with psoriasis vulgaris referred to dermatologists in Semnan, Iran: a crosssectional study. Iran J Dermatology. 2021;24(3):166–71.
Al-Hassany L, Lyons HS, Boucherie DM, Farham F, Lange KS, Marschollek K, Onan D, Pensato U, Storch E, Torrente A. The sense of stopping migraine prophylaxis. J Headache Pain. 2023;24(1):9.
doi: 10.1186/s10194-023-01539-8
pubmed: 36792981
pmcid: 9933401
Sadeghi O, Nasiri M, Saiedi SG. The prevalence of migraine in different parts of Iran: review of the current evidence. Jundishapur J Chronic Disease Care 2015, 4(3).
Tzankova V, Becker WJ, Chan TL. Diagnosis and acute management of migraine. CMAJ. 2023;195(4):E153–8.
doi: 10.1503/cmaj.211969
pubmed: 36717129
pmcid: 9888545
Silva-Néto RP, Jevoux C, Krymchantowski A. Preventive and abortive treatment of migraine with traditional Drugs. The state of the art. Headache Med. 2023;14(3):133–43.
doi: 10.48208/HeadacheMed.2023.27
Kim SA, Choi SY, Youn MS, Pozo-Rosich P, Lee MJ. Epidemiology, burden and clinical spectrum of cluster headache: a global update. Cephalalgia. 2023;43(9):03331024231201577.
doi: 10.1177/03331024231201577
Gaglianone C, Bentivegna E, Martelletti P. What is the best methodology for Headache or Migraine Research? Clinical scales for Headache disorders. edn.: Springer; 2023. pp. 1–21.
In: https://www.niceorguk/search?q=migraine In: Excellence TNIfHaC, editor.
Ashina S, Terwindt GM, Steiner TJ, Lee MJ, Porreca F, Tassorelli C, Schwedt TJ, Jensen RH, Diener H-C, Lipton RB. Medication overuse headache. Nat Reviews Disease Primers. 2023;9(1):5.
doi: 10.1038/s41572-022-00415-0
pubmed: 36732518
Ljubisavljevic S, Ljubisavljevic M, Damjanovic R, Kalinic S. A descriptive review of medication-overuse headache: from pathophysiology to the comorbidities. Brain Sci. 2023;13(10):1408.
doi: 10.3390/brainsci13101408
pubmed: 37891777
pmcid: 10605322
Blair HA. Rimegepant: a review in the Acute Treatment and Preventive Treatment of Migraine. CNS Drugs. 2023;37(3):255–65.
doi: 10.1007/s40263-023-00988-8
pubmed: 36739335
pmcid: 10299922
Tao X, Yan Z, Meng J, Wang W, Dai Q, Zhou Q, Wang Z, Wang Z. The efficacy and safety of atogepant for the prophylactic treatment of migraine: evidence from randomized controlled trials. J Headache Pain. 2022;23(1):1–12.
doi: 10.1186/s10194-022-01391-2
Zduńska A, Cegielska J, Domitrz I. The pathogenetic role of melatonin in migraine and its theoretic implications for pharmacotherapy: a brief overview of the research. Nutrients. 2022;14(16):3335.
doi: 10.3390/nu14163335
pubmed: 36014841
pmcid: 9415653
Faraj HR. Estimation of the serotonin and melatonin hormones levels in patients with migraine in thi–qar governorate-iraq. J Int Pharm Res. 2019;46(4):109–11.
Tyuvina N, Stolyarova A, Chudova A. Long-term maintenance therapy of depressive disorders with antidepressants: experience of using agomelatin. Zhurnal Nevrologii i Psikhiatrii Imeni SS Korsakova. 2021;121(6):87–92.
doi: 10.17116/jnevro202112106187
KARTAL NT, OZBEK-BİLGİN A, YÜCELİK ŞS, HALICI Z. ÇADIRCI E: Protective effects of Agomelatin, a melatonin receptor agonist, on Paracetamol Induced Nephrotoxicity. Hacettepe Univ J Fac Pharm, 39(2):81–9.
Bakkaloğlu U, Babur E, Tan B, Yazgan K, Yalçın B, Yay AH, Gölgeli A. The effect of agomelatin on pain threshold and neurogenesis in depressed male rats. Anatomy: International Journal of Experimental & Clinical Anatomy; 2019. p. 13.
Paulus W, Polasik A. Agomelatin Zur Behandlung Depressiver Episoden–Erste Erfahrungen in Der Schwangerschaft. Z für Geburtshilfe Und Neonatologie. 2021;225(S 01):P037.
Plasencia-García BO, Romero-Guillena SL, Quirós-López A, Ruiz-Doblado S. Agomelatine and migraine management: a successfully treated case series. Therapeutic Adv Psychopharmacol. 2015;5(4):243–5.
doi: 10.1177/2045125315584869
Naguy A, Alamiri B. Successful agomelatine monotherapy for an adolescent with attention deficit hyperactivity disorder and comorbid migraine. CNS Spectr. 2022;27(2):134–5.
doi: 10.1017/S1092852920001923
pubmed: 33092678
Gelfand AA, Allen IE, Grimes B, Irwin S, Qubty W, Greene K, Waung M, Powers SW, Szperka CL. Melatonin for migraine prevention in children and adolescents: a randomized, double-blind, placebo‐controlled trial after single‐blind placebo lead‐in. Headache: The Journal of Head and Face Pain; 2023.
Alkhaffaf WH. Efficacy and tolerability of melatonin versus topiramate in migraine prevention. Arch Venezolanos De Farmacología Y Terapéutica. 2021;40(1):27–32.
Fallah R, Shoroki F, Ferdosian F. Safety and efficacy of melatonin in pediatric migraine prophylaxis. Curr Drug Saf. 2015;10(2):132–5.
doi: 10.2174/1574886309666140605114614
pubmed: 24909684
Gonçalves AL, Ferreira AM, Ribeiro RT, Zukerman E, Cipolla-Neto J, Peres MFP. Randomised clinical trial comparing melatonin 3 mg, Amitriptyline 25 mg and placebo for migraine prevention. J Neurol Neurosurg Psychiatry. 2016;87(10):1127–32.
doi: 10.1136/jnnp-2016-313458
pubmed: 27165014
Liampas I, Siokas V, Brotis A, Vikelis M, Dardiotis E. Endogenous melatonin levels and therapeutic use of exogenous melatonin in migraine: systematic review and meta-analysis. Headache: The Journal of Head and Face Pain. 2020;60(7):1273–99.
doi: 10.1111/head.13828
Long R, Zhu Y, Zhou S. Therapeutic role of melatonin in migraine prophylaxis: a systematic review. Medicine. 2019;98(3).
Mundot Puliappadamb H, Maiti R, Mishra A, Jena M, Ranjan Mishra B. Efficacy and Safety of Melatonin as Prophylaxis for Migraine in adults: a Meta-analysis. Journal of Oral & Facial Pain & Headache; 2022. p. 36.
Tseng PT, Yang CP, Su KP, Chen TY, Wu YC, Tu YK, Lin PY, Stubbs B, Carvalho AF, Matsuoka YJ. The association between melatonin and episodic migraine: a pilot network meta-analysis of randomized controlled trials to compare the prophylactic effects with exogenous melatonin supplementation and pharmacotherapy. J Pineal Res. 2020;69(2):e12663.
doi: 10.1111/jpi.12663
pubmed: 32347977
Farhadi Z, Alidoost S, Behzadifar M, Mohammadibakhsh R, Khodadadi N, Sepehrian R, Sohrabi R, Mirghaed MT, Salemi M, Ravaghi H. The prevalence of migraine in Iran: a systematic review and meta-analysis. Iran Red Crescent Med J. 2016;18(10).
Tsai C-K, Tsai C-L, Lin G-Y, Yang F-C, Wang S-J. Sex differences in chronic migraine: focusing on clinical features, pathophysiology, and treatments. Curr Pain Headache Rep. 2022;26(5):347–55.
doi: 10.1007/s11916-022-01034-w
pubmed: 35218478
Mahović D, Bračić M, Jakuš L, Cvetkovic VV, Krpan M. Effectiveness and safety of erenumab in chronic migraine: a Croatian real-world experience. Clin Neurol Neurosurg. 2022;214:107169.
doi: 10.1016/j.clineuro.2022.107169
pubmed: 35151970
Lipton RB, Goadsby PJ, Smith J, Schaeffler BA, Biondi DM, Hirman J, Pederson S, Allan B, Cady R. Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology. 2020;94(13):e1365–77.
doi: 10.1212/WNL.0000000000009169
pubmed: 32209650
pmcid: 7274916
Nematgorgani S, Gholi Z, Jahromi SR, Togha M, Karimzadeh F. The effect of vitamins b on improving the symptoms of migraine: an overview. Neurosci J Shefaye Khatam. 2020;8(2):119–29.
doi: 10.29252/shefa.8.2.119
Acarsoy C, Fani L, Al-Hassany L, Berghout BP, Koudstaal PJ, Van Den Maassen A, Ikram MK, Bos D. Migraine and the risk of Stroke in a middle-aged and elderly population: a prospective cohort study. Cephalalgia. 2023;43(1):03331024221132008.
doi: 10.1177/03331024221132008
Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, Thomas J. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane database of systematic reviews. 2019;2019(10).
Sati V, Jauhari R, Rao N, Godiyal P, Babbar A. Melatonin: role in the Prophylaxis of Migraine. J Appl Pharm Sci Res. 2022;5(2):17–27.
doi: 10.31069/japsr.v5i2.03
Song T-J, Kim B-S, Chu MK. Therapeutic role of melatonin in migraine prophylaxis: is there a link between sleep and migraine? Prog Brain Res. 2020;255:343–69.
doi: 10.1016/bs.pbr.2020.05.014
pubmed: 33008513